{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T06:12:06Z","timestamp":1772259126623,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1164,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.bbmt.2011.07.014","type":"journal-article","created":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T07:56:31Z","timestamp":1311666991000},"page":"241-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Plerixafor Added to Chemotherapy Plus G-CSF Is Safe\u00a0and Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma or\u00a0Lymphoma"],"prefix":"10.1016","volume":"18","author":[{"given":"Immacolata","family":"Attolico","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Pavone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Ostuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Musso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Crescimanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Martino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Iacopino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Milone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Coluzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Nuccorini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Pascale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"Di Nardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attilio","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2011.07.014_bib1","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.bbmt.2009.11.012","article-title":"Poor mobilization of hematopoietic stem cells\u2014definitions, incidence, risk factors, and impact on outcome of autologous transplantation","volume":"16","author":"Wuchter","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.07.014_bib2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/scd.1.1992.1.329","article-title":"Defining a therapeutic dose of peripheral blood stem cells","volume":"1","author":"Bender","year":"1992","journal-title":"J Hematother"},{"key":"10.1016\/j.bbmt.2011.07.014_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2895.x","article-title":"Effect of CD34+ cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation","volume":"78","author":"Klaus","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2011.07.014_bib4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.bbmt.2008.07.004","article-title":"Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologus transplantation","volume":"14","author":"Pusic","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.07.014_bib5","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1089\/scd.2004.13.598","article-title":"What is the optimum number of CD34+ peripheral blood stem cells for an autologous transplant?","volume":"13","author":"Jillella","year":"2004","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.bbmt.2011.07.014_bib6","first-page":"329","article-title":"Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience","volume":"83","author":"Olivieri","year":"1998","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2011.07.014_bib7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/JCO.1997.15.2.535","article-title":"Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma","volume":"15","author":"Watts","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.07.014_bib8","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/oxfordjournals.annonc.a059007","article-title":"Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size","volume":"5","author":"van der Wall","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2011.07.014_bib9","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/sj.bmt.1701748","article-title":"Using at least 5 \u00d7 10(6)\/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation","volume":"23","author":"Scheid","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.07.014_bib10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.bmt.1705298","article-title":"Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation","volume":"37","author":"Pavone","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.07.014_bib11","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.2000.18.9.1824","article-title":"Randomized cross-over trial of progenitor-cell mobilization: high dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus\u00a0granulocyte-macrophage colony-stimulating factor plus G-CSF","volume":"18","author":"Koc","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.07.014_bib12","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1182\/blood.V98.7.2059","article-title":"Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation","volume":"98","author":"Narayanasami","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.07.014_bib13","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/sj.bmt.1700999","article-title":"Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy","volume":"20","author":"Spitzer","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.07.014_bib14","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1046\/j.1365-2141.2002.03264.x","article-title":"Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF","volume":"116","author":"Demirer","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2011.07.014_bib15","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood-2005-02-0468","article-title":"The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone","volume":"106","author":"Flomenberg","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.07.014_bib16","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.07.014_bib17","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"DiPersio","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.07.014_bib18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.bmt.1705908","article-title":"AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin\u2019s lymphoma, Hodgkin\u2019s disease and multiple myeloma patients previously failing mobilization with chemotherapy and\/or cytokine treatment: compassionate use data","volume":"41","author":"Calandra","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.07.014_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","article-title":"Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)","volume":"71","author":"Velasquez","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.07.014_bib20","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.V84.5.1421.1421","article-title":"Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin","volume":"84","author":"Brugger","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.07.014_bib21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.07.014_bib22","first-page":"247","article-title":"Single platform enumeration of viable CD34+ cells","volume":"17","author":"Keeney","year":"2003","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.bbmt.2011.07.014_bib23","series-title":"Statistics for Medicine","author":"Riffenburgh Robert","year":"2006"},{"key":"10.1016\/j.bbmt.2011.07.014_bib24","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/bmt.2009.318","article-title":"Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study","volume":"45","author":"Musso","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.07.014_bib25","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","article-title":"BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin\u2019s lymphoma","volume":"13","author":"Mills","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.07.014_bib26","article-title":"TEAM (thiotepa, etoposide, cytarabine, melphalan) as conditioning regimen for lymphoma treatment with autologous hematopoietic stem cell transplantation","volume":"43","author":"Carella","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.07.014_bib27","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.bbmt.2009.08.005","article-title":"Successful stem cell remobilization using plerixafor (Mozobil) plus granulocyte colony-stimulating factor in patients with non-Hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol","volume":"15","author":"Micallef","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.07.014_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/bmt.2009.130","article-title":"Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization","volume":"45","author":"Tricot","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.07.014_bib29","first-page":"621","article-title":"Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study","volume":"91","author":"de la Rubia","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2011.07.014_bib30","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2141.2003.04107.x","article-title":"Mobilization of CD34+ cells in elderly patients (>\/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen","volume":"120","author":"Morris","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2011.07.014_bib31","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/annonc\/mdm608","article-title":"High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin\u2019s lymphoma in patients >65 years of age","volume":"19","author":"Hosing","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2011.07.014_bib32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.transci.2008.09.012","article-title":"Factors affecting hematopoietic progenitor cell mobilization: an analysis of 307 patients","volume":"39","author":"Mendrone","year":"2008","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.bbmt.2011.07.014_bib33","first-page":"494","article-title":"Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin\u2019s disease","volume":"86","author":"Canales","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2011.07.014_bib34","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood.V83.12.3787.3787","article-title":"Patient characteristic associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma","volume":"83","author":"Haas","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.07.014_bib35","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1182\/blood.V86.10.3970.bloodjournal86103970","article-title":"Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts","volume":"86","author":"Dreger","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.07.014_bib36","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1046\/j.1365-2141.2001.02498.x","article-title":"Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone","volume":"112","author":"Desikan","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2011.07.014_bib37","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/sj.bmt.1704466","article-title":"Prediction of mobilisation failure in patients with non-Hodgkin\u2019s lymphoma","volume":"33","author":"Kuittinen","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.07.014_bib38","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/sj.leu.2405100","article-title":"Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma","volume":"22","author":"Paripati","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2011.07.014_bib39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/bmt.2009.119","article-title":"Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin\u2019s lymphoma undergoing stem cell mobilization","volume":"45","author":"Dugan","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.07.014_bib40","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/bmt.2010.128","article-title":"The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF","volume":"46","author":"D\u2019Addio","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.07.014_bib41","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/bmt.2010.249","article-title":"Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program","volume":"46","author":"H\u00fcbel","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.07.014_bib42","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1537-2995.2010.02896.x","volume":"51","author":"Worel","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.bbmt.2011.07.014_bib43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/bmt.2008.410","article-title":"Improving stem cell mobilization strategies: future directions","volume":"43","author":"Bensinger","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.07.014_bib44","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1002\/cncr.11414","volume":"97","author":"Tarella","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2011.07.014_bib45","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM199705013361804","article-title":"High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma","volume":"336","author":"Gianni","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2011.07.014_bib46","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bbmt.2008.11.028","article-title":"Treatment with plerixafor in non-Hodgkin\u2019s lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient","volume":"15","author":"Stiff","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.07.014_bib47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.0902-4441.2004.00171.x","article-title":"Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis","volume":"72","author":"Olivieri","year":"2004","journal-title":"Eur J Haematol"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111003041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111003041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:43:14Z","timestamp":1761057794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879111003041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S1083879111003041"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.07.014","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plerixafor Added to Chemotherapy Plus G-CSF Is Safe\u00a0and Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma or\u00a0Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}